Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Does Changing Antiretroviral Therapy in the First Trimester for Pregnancy-Related Concerns Have an Impact on Viral Suppression?
38 Pages Posted: 17 Jul 2018
More...Abstract
Objective: To determine whether changing antiretroviral therapy (ART) during pregnancy in order to follow guidelines because of concern about fetal risks led to poorer virological outcomes.
Methods: All pregnancies in women with HIV1 infection enrolled in the national multicenter prospective French Perinatal cohort were included between 01/2005 and 12/2015, at 14 gestational weeks or more and if the mother was on ART at conception with a plasma viral load < 50 copies/ml. The reasons for a change in the ART were analyzed according to treatment guidelines at the time of the pregnancy, and defined as for pregnancy-related concerns in the absence of reported maternal intolerance. Virological and pregnancy outcomes were studied by survival analysis and logistic regression adjusted for a propensity score established for each patient according to baseline characteristics.
Results: Of 10553 pregnancies in the cohort, 1797 were taking ART at conception and had a viral load <50 copies/mL before 14 weeks' gestation. Of these, 411 changed regimens in the first trimester for pregnancy-related concerns. The proportion of change was statistically higher when initial treatment was clearly contraindicated (OR adjusted: 23.1 [14.0- 38.2]) or was regarded as an alternative option (ORa: 2.2 [1.3-3.7]), as compared to recommended first-line regimens. Treatment changes for pregnancy-related concerns did not lead to poorer virological control, compared to pregnancies without such changes (19.3% vs. 15.6%, HRa: 1.0 [0.7-1.4]).
Conclusions: Changing ART early in pregnancy with the goal of improving fetal and pregnancy outcomes did not appear to have a destabilizing effect on viral suppression.
Financial Support: This work was supported by the French Agence Nationale de Recherche sur le SIDA (ANRS).
Potential Conflicts of Interest: The authors declare no conflicts of interest in relation with this work.
Ethics Approval Statement: The French Perinatal Cohort (ANRS EPF CO1/CO11) is a prospective, obervational study ongoing since 1985 in 90 perinatal centers throughout France (8) which includes all pregnancies in women with HIV-1 and/or HIV-2 with their informed consent and ethics committee (Comité de Protection des Personnes) approval.
Keywords: HIV, pregnancy, antiretroviral therapy, preconception care, treatment switch, guidelines, viral suppression
Suggested Citation: Suggested Citation